1.62
price up icon2.53%   0.04
after-market After Hours: 1.61 -0.01 -0.62%
loading
Pacific Biosciences Of California Inc stock is traded at $1.62, with a volume of 11.03M. It is up +2.53% in the last 24 hours and up +6.58% over the past month. Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.58
Open:
$1.57
24h Volume:
11.03M
Relative Volume:
1.64
Market Cap:
$503.55M
Revenue:
$160.03M
Net Income/Loss:
$-128.58M
P/E Ratio:
-3.7957
EPS:
-0.4268
Net Cash Flow:
$-121.21M
1W Performance:
+18.25%
1M Performance:
+6.58%
6M Performance:
+16.55%
1Y Performance:
+32.79%
1-Day Range:
Value
$1.52
$1.63
1-Week Range:
Value
$1.34
$1.63
52-Week Range:
Value
$1.07
$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Name
Name
Pacific Biosciences Of California Inc
Name
Phone
650-521-8000
Name
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Name
Employee
485
Name
Twitter
@pacbio
Name
Next Earnings Date
2026-11-04
Name
Latest SEC Filings
Name
PACB's Discussions on Twitter

Compare PACB vs ABT, MDT, SYK, BSX, EW

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PACB icon
PACB
Pacific Biosciences Of California Inc
1.62 503.55M 160.03M -128.58M -121.21M -0.4268
ABT icon
ABT
Abbott Laboratories
101.29 175.27B 46.59B 5.41B 7.38B 3.0938
MDT icon
MDT
Medtronic Plc
88.64 113.38B 36.36B 4.84B 5.43B 3.7261
SYK icon
SYK
Stryker Corp
272.36 104.47B 25.27B 3.34B 4.57B 8.6334
BSX icon
BSX
Boston Scientific Corp
43.92 63.65B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
86.29 49.74B 6.30B 1.07B 1.09B 1.8406

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-06-26 Downgrade Barclays Equal Weight → Underweight
Nov-11-24 Downgrade UBS Buy → Neutral
Jun-03-24 Resumed Jefferies Buy
Apr-22-24 Downgrade JP Morgan Overweight → Neutral
Apr-18-24 Downgrade Goldman Buy → Neutral
Dec-14-23 Initiated Guggenheim Neutral
Dec-14-23 Initiated Stephens Overweight
Dec-13-23 Initiated Wolfe Research Peer Perform
Nov-17-23 Upgrade UBS Neutral → Buy
Oct-31-23 Upgrade Cantor Fitzgerald Neutral → Overweight
Sep-28-23 Initiated Bernstein Outperform
Jul-05-23 Resumed JP Morgan Overweight
Jun-30-23 Initiated Goldman Buy
May-10-23 Initiated Barclays Equal Weight
Mar-31-23 Upgrade TD Cowen Market Perform → Outperform
Feb-02-23 Initiated UBS Neutral
Jan-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-05-23 Initiated Scotiabank Sector Outperform
Jan-21-22 Resumed Cantor Fitzgerald Overweight
Jan-06-22 Resumed Piper Sandler Neutral
Oct-15-21 Resumed Cowen Market Perform
Sep-27-21 Initiated Canaccord Genuity Buy
Feb-11-21 Upgrade Piper Sandler Neutral → Overweight
Nov-03-20 Downgrade Piper Sandler Overweight → Neutral
Oct-02-20 Upgrade JP Morgan Neutral → Overweight
Sep-09-20 Initiated Morgan Stanley Equal-Weight
Jun-02-20 Resumed Cantor Fitzgerald Overweight
Mar-09-20 Resumed Cantor Fitzgerald Overweight
Oct-15-19 Upgrade Piper Jaffray Neutral → Overweight
Apr-02-19 Downgrade Stephens Overweight → Equal-Weight
Oct-19-18 Initiated Cowen Outperform
Nov-03-17 Downgrade First Analysis Sec Overweight → Equal-Weight
Sep-28-17 Downgrade CL King Buy → Neutral
Nov-03-16 Reiterated Cantor Fitzgerald Buy
Jun-27-16 Initiated CL King Buy
Apr-15-16 Initiated First Analysis Sec Overweight
Feb-04-16 Downgrade Piper Jaffray Overweight → Neutral
Jan-04-16 Reiterated Cantor Fitzgerald Buy
Oct-23-15 Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15 Initiated Cantor Fitzgerald Buy
Feb-04-15 Reiterated Maxim Group Buy
Sep-26-13 Reiterated Maxim Group Buy
Jan-14-13 Reiterated Maxim Group Buy
View All

Pacific Biosciences Of California Inc Stock (PACB) Latest News

pulisher
Sep 25, 2026

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo! Finance Canada

Sep 25, 2026
pulisher
Sep 25, 2026

Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 25, 2026
pulisher
Sep 24, 2026

How to build the scientific case that gets your grant funded - PacBio

Sep 24, 2026
pulisher
Sep 22, 2026

PACB Stock Firms Up Ahead Of Morgan Stanley Healthcare Chat - StocksToTrade

Sep 22, 2026
pulisher
Sep 21, 2026

Pacific Biosciences of California (PACB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 21, 2026
pulisher
Sep 20, 2026

Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push - Yahoo Finance

Sep 20, 2026
pulisher
Sep 17, 2026

Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance

Sep 17, 2026
pulisher
Sep 11, 2026

CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating - Moomoo

Sep 11, 2026
pulisher
Sep 10, 2026

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Sep 10, 2026
pulisher
Sep 10, 2026

How to build a more competitive grant proposal without losing your research time to it - PacBio

Sep 10, 2026
pulisher
Sep 09, 2026

Pacific Biosciences Coverage Assumed by UBS at Neutral - Moomoo

Sep 09, 2026
pulisher
Sep 07, 2026

Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks - The Globe and Mail

Sep 07, 2026
pulisher
Sep 04, 2026

Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? - Eastern Progress

Sep 04, 2026
pulisher
Sep 04, 2026

PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference - marketscreener.com

Sep 04, 2026
pulisher
Sep 04, 2026

PACB stock gains as PacBio highlights sequencing strength ahead Morgan Stanley conference - ad-hoc-news.de

Sep 04, 2026
pulisher
Sep 03, 2026

PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference - marketscreener.com

Sep 03, 2026
pulisher
Sep 03, 2026

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - TradingView

Sep 03, 2026
pulisher
Sep 02, 2026

PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test - TradingView

Sep 02, 2026
pulisher
Sep 02, 2026

3 Reasons to Sell PACB and 1 Stock to Buy Instead - Yahoo Finance

Sep 02, 2026
pulisher
Aug 29, 2026

Pacific Biosciences (PACB) Tumbles 9.7% to $1.40, Nears Critical Support at $1.33Stock News - vinanet.vn

Aug 29, 2026
pulisher
Aug 29, 2026

PACB Q2 2026 Earnings: Wider-than-Expected Per-Share Loss Drives 9.68% SelloffEstimate Uncertainty - careplusvn.com

Aug 29, 2026
pulisher
Aug 25, 2026

Pacific (PACB) EPS and Revenue: EPS Misses Its Estimate in the Reported Period; Share Response: The Stock Loses 5.19% on the DayEarnings Preview - careplusvn.com

Aug 25, 2026
pulisher
Aug 22, 2026

Pacific (PACB) Momentum: Ends Higher by 9.76% at $1.35 for the Current Session; Price Levels - careplusvn.com

Aug 22, 2026
pulisher
Aug 21, 2026

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts - MarketBeat

Aug 21, 2026
pulisher
Aug 19, 2026

Pacific (PACB) Earnings Update: EPS Misses Its Estimate on the Day; Trading Response: Shares Close 11.40% Higher in Latest TradingEarnings Weakness Phase - Vinanet

Aug 19, 2026
pulisher
Aug 19, 2026

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com - Investing.com South Africa

Aug 19, 2026
pulisher
Aug 18, 2026

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - Stock Titan

Aug 18, 2026
pulisher
Aug 17, 2026

Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

Pacific Biosciences of California Inc (PACB) (Q2 2026) Earnings - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing (Aug 17, 2026) - Stock Titan

Aug 17, 2026
pulisher
Aug 16, 2026

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - MarketBeat

Aug 16, 2026
pulisher
Aug 14, 2026

ARK reports 9.59% stake in Pacific Biosciences (PACB) - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call - Yahoo Finance

Aug 14, 2026
pulisher
Aug 11, 2026

PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs - Stock Titan

Aug 11, 2026
pulisher
Aug 10, 2026

Measuring – not guessing – the true path - PacBio

Aug 10, 2026
pulisher
Aug 10, 2026

Weekly Recap: PACB cuts 2026 revenue guide and Mark Van Oene named CEO - TradingView

Aug 10, 2026
pulisher
Aug 09, 2026

Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC - MarketBeat

Aug 09, 2026
pulisher
Aug 08, 2026

Pacific Biosciences of California, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-08-08 - Seeking Alpha

Aug 08, 2026
pulisher
Aug 08, 2026

Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29 - simplywall.st

Aug 08, 2026
pulisher
Aug 08, 2026

Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen - MarketBeat

Aug 08, 2026
pulisher
Aug 06, 2026

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3 - Moomoo

Aug 06, 2026
pulisher
Aug 06, 2026

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

Pacific Biosciences (PACB) Drops 6.5% to $1.22, Testing Key Support LevelSmart Money Flow Stocks - careplusvn.com

Aug 06, 2026
pulisher
Aug 06, 2026

Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB) - Seeking Alpha

Aug 06, 2026
pulisher
Aug 06, 2026

Pacific Biosciences of California Q2 Earnings Call Highlights - TradingView

Aug 06, 2026
pulisher
Aug 05, 2026

Pacific Biosciences of California, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce - Moomoo

Aug 05, 2026

Pacific Biosciences Of California Inc Stock (PACB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
ZBH ZBH
$91.04
price up icon 1.51%
STE STE
$208.93
price up icon 0.08%
PHG PHG
$24.96
price up icon 1.67%
$66.63
price up icon 0.38%
$86.62
price down icon 0.97%
EW EW
$86.29
price up icon 0.65%
Cap:     |  Volume (24h):